Lenalidomide for Treatment of Myelodysplastic Syndromes

E-ISSN： 1873-4286|18|22|3198-3203

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.18, Iss.22, 2012-07, pp. : 3198-3203

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

5-Azacytidine for the treatment of myelodysplastic syndromes

By Krawczyk Janusz Keane Niamh Freeman Ciara Louise Swords Ronan O'Dwyer Michael Giles Francis J

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 9, 2013-06 ,pp. : 1255-1268

Informa Healthcare

Access to resources Recommend Favorite

Arsenic trioxide for the treatment of myelodysplastic syndromes

By Vey Norbert

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 3, 2004-03 ,pp. : 613-621

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic spectrum in the treatment of myelodysplastic syndromes

By Hofmann Wolf-K Baldus Claudia Uharek Lutz Thiel Eckhard

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 12, 2004-12 ,pp. : 2451-2458

Informa Healthcare

Access to resources Recommend Favorite

The role of azacitidine in the treatment of myelodysplastic syndromes

By Abdulhaq Haifaa Rossetti James M

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 12, 2007-12 ,pp. : 1967-1975

Informa Healthcare

Access to resources Recommend Favorite

Novel Biospecific Agents for the Treatment of Myelodysplastic Syndromes

By Gotlib Jason Greenberg Peter L.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 1, Iss. 4, 2003-11 ,pp. : 473-480

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite